Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Inc (NYSE: ABBV) reports

AbbVie Sales Lag As Humira Competition Heats Up And U.S. Biosimilars Loom

AbbVie Sales Lag As Humira Competition Heats Up And U.S. Biosimilars Loom

AbbVie stock inched ahead Wednesday despite a sales miss for its biggest moneymaker, Humira, as biosimilar competition heats up.

Investors Business Daily

AbbVie: Q4 Earnings Insights

AbbVie: Q4 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q4 earnings results on Wednesday, February 2, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Earnings Outlook For AbbVie

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will likely report an Earnings Per Share (EPS) of $3.28.

Ocean Shipper Matson Leads Five Stocks Showing Strength In Volatile Market

Ocean shipper Matson is in buy range and among five stocks showing unusual relative strength in a weak market.

Investors Business Daily

AbbVie Whale Trades For January 25

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Analyst Ratings For AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

inkl

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On AbbVie

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 19 strange trades.

$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much

$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 2.43% on an annualized basis.

3 Buy-Rated Stocks Yielding More than 4%

3 Buy-Rated Stocks Yielding More than 4%

As the stock market is expected to remain volatile owing to the anticipated interest rate hikes to control inflation, it could be wise to bet on fundamentally strong dividend-yielding stocks AbbVie (ABBV), Philip Morris (PM), and Vector Group (VGR) for securing a steady income stream. These stocks are rated ‘Buy’…

$FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older$

FDA Approves AbbVie's Upadacitinib For Refractory Atopic Dermatitis In Patients 12 Years & Older

The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks

The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks

The Kiplinger Dividend 15 are poised to benefit as falling interest rates lure investors back to dividend-paying stocks.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Johnson & Johnson (

Air Products Chemicals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

249,203 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play